Biotech followers and investors tracking Mana.bio have likely noticed a recent flurry of updates—but some of that information contained critical errors. Today, Mana.bio issued an official correction to clarify key details about its non-viral gene therapy pipeline, partnerships, and clinical timelines.
What Prompted the Mana.bio Correction?
The correction addresses inaccuracies in a September 12, 2024 update that was inadvertently circulated to media outlets and investor databases. Mana.bio’s communications team identified three core errors in the initial release, all of which are now formally corrected.
Key Errors Fixed in the Official Correction
- MB-101 IND Timeline: The initial update incorrectly stated the lead cystic fibrosis candidate would file an IND in Q3 2024. The corrected timeline pushes this to Q1 2025, to allow for additional preclinical safety testing.
- Partnership Scope: A misstatement claimed Mana.bio had signed a 3-program co-development deal with Pfizer. The correction clarifies this is a single-target research collaboration focused on liver-delivered gene therapies.
- Preclinical Efficacy Data: Early data for MB-205 (Duchenne muscular dystrophy candidate) was overreported. Corrected results show a 34% improvement in muscle function, not the 42% initially shared.
Verified Accurate Updates Confirmed by Mana.bio
Alongside fixing errors, the correction reaffirms several key milestones that remain on track for the biotech startup:
- MB-101 preclinical data now shows 92% lung tissue transduction efficiency, a 7-point increase from prior reported figures.
- Dr. Sarah Chen, former Head of Clinical Development at Spark Therapeutics, has joined as VP of Clinical Development effective this week.
- Mana.bio has expanded its manufacturing partnership with Catalent to secure supply for its first-in-human Phase 1 trial for MB-101.
- The company’s Series B extension round remains oversubscribed, with $45M raised to date against a $50M target.
Why This Correction Matters for Stakeholders
For investors, accurate clinical timelines and partnership terms are critical for valuation and portfolio planning. Patients and advocacy groups rely on correct efficacy data to understand potential treatment options. Industry partners also need clarity on deal scope to align resources and expectations.
Mana.bio noted that this correction is part of a broader push to improve transparency and reduce misinformation in the fast-moving gene therapy sector.
How to Access the Full Correction Notice
The complete, verified correction notice is available exclusively on Mana.bio’s official newsroom page: https://mana.bio/news/official-correction-sept-2024.
All future pipeline updates, partnership announcements, and financial disclosures will be posted first to this channel. Stakeholders are encouraged to subscribe to Mana.bio’s monthly newsletter to receive verified alerts directly.
Conclusion
Mana.bio remains a leading player in non-viral gene delivery, with a pipeline targeting high-unmet-need genetic diseases. This correction ensures all stakeholders have access to accurate, up-to-date information as the company advances its clinical programs. Always verify biotech updates through official company channels to avoid relying on outdated or incorrect third-party reports.
Comments are closed, but trackbacks and pingbacks are open.